BBIOBridgeBio Pharma, Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, quality weak, and heavy debt (CCC). Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Weak, deteriorating fundamentals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$4.6M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -93% · now 24% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BBIO take a bad year?
The deepest fall in BBIO's price history on file is −93%; it is 24% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Altman Z-score
- -3.65
Altman Z-score · distress zone, below 1.8
- Cash runway
- 1.6 years
Cash runway · burning $109M a quarter at the current rate
- Annualised volatility
- 52%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $2.65B
- Cash and short-term investments
- $720M
- Net debt
- $1.93B
- EBITDA, trailing twelve months
- −$494M
- Operating profit, trailing twelve months
- −$498M
- Annualised volatilitytwo years of daily moves
- 52%
- Worst drawdown on file
- −93%
- Below its 52-week high
- 24%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.